Ceria Therapeutics, Inc. Awarded a $2,100,000 SBIR Grant to Advance Development of a Novel Treatment for Acute Lung Injuries, Acute Lung Failure, and Acute Respiratory Distress Syndrome

Tucson, AZ – September 19, 2023 – Ceria Therapeutics, Inc.(Ceria), an Arizona-based biotech startup focusing on the development of novel therapeutics to address several inflammatory diseases, today announced the company has received a third Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH). This award is directed to the development of CTX-002 for the treatment of progressive inflammatory lung disorders, including Acute Lung Injuries (ALI), Acute Lung Failure (ARF), and Acute Respiratory Distress Syndrome (ARDS).